Dose Insider / Analyses / GLP-1 constipation

Constipation on a GLP-1How Common It Is, How Long It Lasts and What Helps

Updated November 20, 2026 路 23 min read 路 FDA labels 2026, STEP pooled analysis, AGA-ACG guideline 2023

Constipation is one of the common side effects of GLP-1 medicines, and the slowest one to pass. In the label trials it was reported by 24% of adults on Wegovy 2.4 mg, 11% to 17% on Zepbound, 6% to 7% on Mounjaro and 3.1% to 5% on Ozempic, against 1% to 11% on placebo. In the pooled Wegovy trials a single episode lasted a median of 47 days.

47 daysthe median length of one episode of constipation on Wegovy 2.4 mg; 35 days on placebo
People reporting constipationLabel trials, share of participantsWEGOVY2.4 mg24%Placebo11%ZEPBOUND5 mg17%Placebo5%People reportingconstipationLabel trials, share of participantsWEGOVY2.4 mg24%Placebo11%ZEPBOUND5 mg17%Placebo5%

One episode on Wegovy lasted a median of 47 days, against 35 on placebo.

On this page

The first steps in the U.S. government's patient guidance are more fiber, more liquids and regular activity, and among laxatives polyethylene glycol carries the strongest recommendation in the 2023 gastroenterology guideline. Constipation with constant abdominal pain, vomiting or an inability to pass gas needs a doctor right away.1,2,5,6,7

How common constipation is on each medicine

Each label has a table of the reactions reported in its placebo-controlled trials. These are the rows for constipation.

MedicinePlaceboOn the drug, by weekly dose
Wegovy (semaglutide), 68-week trials11%2.4 mg24%
Wegovy, 72-week trials of the higher dose8%2.4 mg19%7.2 mg20%
Zepbound (tirzepatide)5%5 mg17%10 mg14%15 mg11%
Mounjaro (tirzepatide)1%5 mg6%10 mg6%15 mg7%
Ozempic (semaglutide)1.5%0.5 mg5%1 mg3.1%

Prescribing information for Wegovy, Zepbound, Mounjaro and Ozempic, section 6.1.1,2,3,4

Constipation, by medicine and doseFDA labels
Medicine

A person counts once however many episodes they had, and mild reports count the same as severe ones. Compare each medicine with its own placebo group; the trials enrolled different people.

Three things stand out in these rows.

The first is that the medicines for weight report constipation far more often than the same molecules sold for diabetes. Wegovy and Ozempic are both semaglutide, at 24% and at 3.1% to 5%. Zepbound and Mounjaro are both tirzepatide at the same three doses, at 11% to 17% and at 6% to 7%. The labels do not explain the gap. The placebo groups differ in the same direction, 5% to 11% in the weight trials and 1% to 1.5% in the diabetes trials, which suggests that part of it comes from who took part and how the trials were run.1,2,3,4

The second is that a higher dose does not mean more constipation. On Zepbound the rate falls as the dose rises, from 17% on 5 mg to 11% on 15 mg. On Ozempic it was 5% on 0.5 mg and 3.1% on 1 mg. On Mounjaro it is flat. In the trials of the higher Wegovy dose, 7.2 mg and 2.4 mg were one point apart. Nausea and vomiting behave the other way: on all four labels they are more frequent on the highest dose than on the lowest.1,2,3,4

The third is the size of the placebo rows. Eleven percent of adults on placebo injections reported constipation in the Wegovy trials. The excess that can be put down to the drug is the difference: 13 points for Wegovy 2.4 mg, 6 to 12 points for Zepbound, 5 to 6 points for Mounjaro and 1.6 to 3.5 points for Ozempic.

The Zepbound label notes that its row combines two reported terms, constipation and hard feces. The Mounjaro label notes that the percentages count patients who reported at least one occurrence.2,4 For teenagers, the Wegovy label lists constipation among the gut reactions that were more frequent on the drug than on placebo in its pediatric trial, without giving the percentage.1

What counts as constipation

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health, describes constipation as a condition in which a person may have:7

It adds that people have different patterns and that only the person knows what is normal for them. So a change from your own pattern matters more than the number three. NIDDK also calls constipation a symptom and not a disease, one that may last a short or a long time.7

Constipation is common without any medicine. NIDDK puts it at about 16 of every 100 adults, and about 33 of every 100 adults aged 60 and older. The gastroenterology guideline estimates that the chronic form with no identified cause affects 8% to 12% of the U.S. population.6,7 That background is why the placebo rows above are not zero, and why an episode during treatment is not always the drug's doing.

Why a GLP-1 causes constipation

No trial has pinned down the cause, and the sources say so. The authors of the pooled analysis of the Wegovy trials wrote that changes in the rate of transit through the lower gut may be responsible for constipation and diarrhea, although evidence is lacking. They added that the longer course of constipation may be because of the effects of this class of drugs on gut motility.5 What can be said with sources is this.

When it starts and how long it lasts

The best measurement comes from a pooled analysis of three of the 68-week trials of Wegovy 2.4 mg, in which 24.2% of people on the drug and 11.1% on placebo reported constipation.5 It found three things.

My episode against the trialsWharton 2022

A median means half of the episodes were shorter and half were longer. The figures are for Wegovy 2.4 mg; no label or paper we opened reports the length of an episode on Zepbound, Mounjaro or Ozempic.

Two details of that result are easy to miss. The first is that constipation was slow on placebo too, at 35 days. Part of the length belongs to constipation itself and not to the drug: the drug added about 12 days to the median and doubled the number of people affected. The second is that the curve at week 10 went flat and did not turn down, unlike nausea after its peak. In a fourth trial, people who had already completed 20 weeks on the drug and then continued it saw the share with constipation decrease over time.5

Nearly all stomach and gut events in the pooled trials were rated mild or moderate, 98.1% of them, and 99.5% were not serious. Reactions of this kind as a group ended treatment for 4.3% of people on Wegovy.5 The analysis was funded by Novo Nordisk, the maker of Wegovy.

Fiber first: what the guidance says and how much a day holds

NIDDK's first instruction for treating constipation at home is to change what you eat and drink: eat more high-fiber foods, and drink plenty of water and other liquids when you eat more fiber or take a fiber supplement. It gives the target as 22 to 34 grams of fiber a day for adults, depending on age and sex, and says to add fiber a little at a time so the body gets used to the change.7 The nutrition advisory written for people on GLP-1 therapy says the same for constipation: adequate fluids and fiber from foods, with a gradual increase.8

The targets by age and sex come from the Dietary Guidelines for Americans.9

AgeWomen gMen g
19 to 302834
31 to 502531
51 and older2228

Dietary Guidelines for Americans, 2020-2025, Appendix 1.9

The gastroenterology guideline quotes a rule that scales with how much a person eats, from the Academy of Nutrition and Dietetics: 14 grams of fiber for every 1,000 calories.6 By that rule a 1,200-calorie day calls for about 17 grams. Reaching the table's 22 to 34 grams on a plate that small means choosing foods with more fiber in each bite.

These are the densest common sources, per portion, from the U.S. Department of Agriculture's food database.10

Food and portionFiber gCalories
Chia seeds, 1 oz9.8138
Raspberries, 1 cup8.064
Lentils, cooked, 陆 cup7.8115
Black beans, cooked, 陆 cup7.5114
Chickpeas, cooked, 陆 cup6.2134
Broccoli, cooked, 1 cup5.155
Avocado, 陆 cup cubes5.0120
Apple with skin, 1 medium4.495
Oatmeal, cooked, 1 cup4.0166
Baked potato with skin, 1 medium3.8161
Almonds, 1 oz3.5164
Prunes, 53.4114
Banana, 1 medium3.1105

USDA FoodData Central, SR Legacy.10

The foods that fill a small, protein-first day are at the other end. Chicken breast, salmon, tuna, eggs, Greek yogurt and cottage cheese have no fiber at all in the same database, and half a cup of white rice has 0.3 grams.10 NIDDK names meat, fast food, chips and prepared and processed foods as the ones to cut back when constipated, because they have little to no fiber.7 The counter below opens with a day of that kind so you can see how far it falls short, and then change it.

My fiber, countedUSDA data
I am
Age
Foods with fiber
Foods with little or none
Shortcuts

Log meals as you eat them and the app keeps the running total.

Open the app

Each tap adds one portion; tap again for a second and a third, and a fourth tap removes the food. The low-fiber day is an example we put together, not a measured diet. The numbers describe the foods and are not a prescription.

Fiber has a ceiling and a cost. The guideline notes that there is usually no benefit to raising total fiber above 25 to 30 grams a day, and that bloating and abdominal discomfort are its common side effects.6 It also cuts both ways early in treatment. For nausea in the first days after a dose, the nutrition advisory suggests avoiding high-fiber and fatty foods.8 If nausea and constipation come together, the gradual increase that NIDDK and the advisory both ask for matters more.

Prunes, kiwifruit and psyllium in trials

The nutrition advisory names prunes and other dried fruit as a way to raise fiber for constipation on a GLP-1.8 Two randomized trials have tested foods of this kind against psyllium, the fiber supplement. Neither enrolled people on a GLP-1. Both recruited adults with constipation in general.

In the first, 40 constipated adults took dried plums, 50 grams twice a day, and psyllium, 11 grams twice a day, for three weeks each, in random order with a week between. Each treatment supplied 6 grams of fiber a day. The number of complete spontaneous bowel movements per week and the consistency of the stool improved more with the dried plums than with psyllium (P below 0.05). Straining and the global symptom rating did not differ between the two, and both were rated equally palatable.11

In the second, 79 adults with chronic constipation at a U.S. medical center were assigned to two green kiwifruit a day, 100 grams of prunes a day or 12 grams of psyllium a day for four weeks. The share who responded was similar across the three. The weekly rate of complete spontaneous bowel movements rose with all three, stool consistency improved with kiwifruit and with prunes, and straining improved with all three. Adverse events were most common with psyllium and least common with kiwifruit, and fewer people were dissatisfied with kiwifruit than with the other two.12

The amounts matter on a small appetite. By the USDA figures above, 100 grams of prunes is about ten prunes and carries about 240 calories and 7 grams of fiber, which is a fifth of a 1,200-calorie day.10 Both trials were small, and the second was only partly randomized, so they show that these foods can work and say little about how much better one is than another.

Liquids

NIDDK ties liquids to fiber: water and other liquids, such as naturally sweetened fruit and vegetable juices and clear soups, help the fiber work better and make stools softer and easier to pass. It gives no single number and says to ask a health care professional how much to drink based on size, health, activity level and where you live.7 The gastroenterology guideline makes the same point about supplements: adequate hydration should be encouraged with the use of fiber.6

There is a second reason to keep liquids up on these medicines. All four labels carry a warning about acute kidney injury due to volume depletion, the loss of fluid that can follow vomiting or diarrhea.1,2,3,4 We could not open a primary source for a daily water target, so this page does not give one.

Movement and routine

The rest of NIDDK's home treatment costs nothing.7

Laxatives: what the guideline found for each one

When food, liquids and habits are not enough, NIDDK says a health care professional may recommend a laxative for a short time and will say which type suits you. It lists five kinds sold without a prescription: fiber supplements, osmotic agents, stool softeners, lubricants such as mineral oil, and stimulants. It adds that stimulants should be used only if constipation is severe or other treatments have not worked.7

The fullest review of how well each one works is the 2023 guideline written jointly by the American Gastroenterological Association and the American College of Gastroenterology. Its panel pooled the randomized trials, issued ten recommendations and graded each as strong or conditional, with the certainty of the evidence behind it.6

AgentKindRecommendation, certaintyExtra bowel movements a week against placebo
Psyllium (fiber supplement)FiberConditional, low2.32
Polyethylene glycol (PEG)OsmoticStrong, moderate2.30
Magnesium oxideOsmoticConditional, very low3.59
LactuloseOsmoticConditional, very low; after over-the-counter agents0.35
Bisacodyl or sodium picosulfateStimulantStrong, moderate; short term or rescue4.04
SennaStimulantConditional, low7.6
Lubiprostone (prescription)SecretagogueConditional, low1.98
Linaclotide (prescription)SecretagogueStrong, moderate1.97
Plecanatide (prescription)SecretagogueStrong, moderate1.66
Prucalopride (prescription)Serotonin type 4 agonistStrong, moderate0.96 complete movements

AGA-ACG guideline 2023. Spontaneous bowel movements per week, mean difference from placebo; for prucalopride the pooled figure we read is for complete spontaneous bowel movements.6

Ten recommendations, side by sideAGA-ACG 2023
Show
Agent

Mint bars carry a strong recommendation and grey bars a conditional one; the chosen agent is coral. A missing bar means the pooled figure for that measure is not among the ones we read. Costs are the guideline's estimates per month in U.S. dollars and may not be the exact cost. Doses are on each product's label and are not given here.

The table needs five cautions before anyone reads it as a ranking.

It is not about GLP-1 medicines. The guideline covers chronic constipation with no identified cause in otherwise healthy adults. Its panel excluded studies of constipation due to other medical conditions, and it says the guideline does not apply to pregnancy or to constipation caused by opioids.6 None of the sources on this page tested a laxative in people constipated by a GLP-1. The guideline is the nearest evidence we could open. The nutrition advisory for GLP-1 therapy, which is expert opinion and not a trial, names magnesium citrate, fiber supplements or capsules and polyethylene glycol 3350 as options, and says stool softeners may help in avoiding straining.8

The biggest number has the weakest footing. Senna's 7.6 extra movements a week comes with a conditional recommendation on low certainty. The dose in the trials was higher than the doses commonly used, 83% of the people assigned to senna reduced their dose during the trial, and abdominal pain and cramping may occur at higher doses. Magnesium oxide's figure rests on two trials with 94 participants, both conducted in Japan, at doses higher than those typical in practice. The panel says to avoid it in people with kidney insufficiency because of the risk of too much magnesium in the blood.6

PEG is the one with a strong recommendation and a long record. Besides 2.30 more bowel movements a week, it brought 2.90 more complete movements, and 312 more people of every 1,000 met the trials' definition of response. The response has been shown to last over six months. Its side effects are abdominal distension, loose stool, flatulence and nausea. The panel adds that a fiber supplement can be tried first for mild constipation, or used together with PEG, and that among fiber supplements only psyllium appears to be effective.6

Two familiar names are weak or missing. Lactulose added 0.35 bowel movements a week in the one trial that measured it, which the panel reads as little to no effect, although a second trial found more people reporting relief. Docusate, the common stool softener, was part of the panel's search and received no recommendation; the guideline notes a paucity of data for it.6

Stimulants are for the short term. The strong recommendation for bisacodyl or sodium picosulfate is for short-term use, defined as daily use for four weeks or less, or as rescue therapy. Their most common side effects are abdominal pain, cramping and diarrhea, and prolonged or excessive use can cause diarrhea and electrolyte imbalance. Sodium picosulfate is not sold on its own in the United States. Senna is also present in many laxative teas, where the guideline notes the dose may be difficult to calculate.6

The last four agents are ones NIDDK describes as medicines a doctor may prescribe. Each of their recommendations is for adults who do not respond to over-the-counter agents, and the guideline estimates their cost at $374 to $563 a month, against under $50 for each of the others and $10 to $45 for PEG.6,7 NIDDK's advice for anyone who has taken laxatives for a long time and cannot have a bowel movement without one is to talk with a doctor about how to stop slowly.7

Other medicines that constipate

A GLP-1 is often not the only thing on the list. NIDDK names these medicines and supplements as ones that can make constipation worse:7

Calcium channel blockers and diuretics are widely used for blood pressure, so the list deserves a look from anyone who takes a GLP-1 alongside other prescriptions. NIDDK's instruction is the same for all of them. If you think a medicine or supplement is causing constipation, talk with your doctor, who may change the dose or suggest a different one. Do not change or stop any medicine or supplement without talking with a health care professional.7 NIDDK's list of health problems that cause constipation also includes diabetes and hypothyroidism.

Does changing the dose help?

The label tables give no reason to expect it. Constipation was no more frequent on the higher doses of any of the four medicines, and on Zepbound and Ozempic it was reported less often on the higher doses than on the lower ones.2,3 Those are comparisons between groups of people, though, and they do not show what happens to one person who steps down.

The labels do leave room to slow down. The Wegovy label says that if a patient does not tolerate a dose during escalation, the prescriber can consider delaying the next step for four weeks. The Zepbound label says to consider treatment response and tolerability when selecting the maintenance dose, and a lower maintenance dose if the current one is not tolerated.1,2 Both are decisions for the prescriber, and both were written about tolerability in general and not about constipation.

In the pooled Wegovy trials the timing points the same way. Constipation appeared early, held level from about week 10, and eased in people who stayed on the drug.5

When it is more than constipation

All four labels list, among the reactions reported after approval, ileus, intestinal obstruction, and severe constipation including fecal impaction. Ileus is a bowel that has stopped moving, and impaction is hardened stool that cannot be passed. The labels note that these reports are voluntary and come from a population of uncertain size, so their frequency cannot be reliably estimated and a causal link to the drug cannot always be established.1,2,3,4

Each label also has a warning headed "Severe Gastrointestinal Adverse Reactions". It gives the share of people in the trials who had a severe reaction of the stomach or gut of any kind.

MedicinePlaceboOn the drug
Wegovy injection, adult weight trials0.9%4.1%
Zepbound1%5 mg1.7%10 mg2.5%15 mg3.1%
Mounjaro0.9%5 mg1.3%10 mg0.4%15 mg1.2%
Ozempic0%0.5 mg0.4%1 mg0.8%

Prescribing information, section 5, "Severe Gastrointestinal Adverse Reactions".1,2,3,4

These figures cover every kind of gut reaction, and the labels do not give a separate number for severe constipation. None of the four medicines is recommended in people with severe gastroparesis, a stomach that empties too slowly.1,2,3,4

NIDDK's rule for constipation from any cause is to see a doctor right away if it comes with any of the following:7

It also says to see a doctor, without the urgency, if symptoms do not go away with self-care or if there is a family history of colon or rectal cancer.7 On a GLP-1 two of the urgent signs are harder to read, because vomiting is a common reaction to the drug and weight loss is its purpose. That is a reason to tell the prescriber about them, and no reason to dismiss them.

Constipation, plus what?NIDDK
Along with constipation I have
Also true for me

The list is NIDDK's and applies to constipation from any cause. It cannot examine you. If something feels seriously wrong, do not wait for a page to agree.

If you take the medicine for diabetes

Ozempic and Mounjaro, the versions approved for type 2 diabetes, have the lowest rows in the first table: 3.1% to 5% and 6% to 7%, against 1.5% and 1% on placebo.3,4 The drug's own excess is small, a few points. The rest of the picture can be larger than the table suggests, because diabetes is on NIDDK's list of conditions that cause constipation and so are several medicines taken alongside it.7 The steps are the same as for anyone else.

Constipation and diarrhea on the same medicine

The same labels report diarrhea more often than constipation at every dose: 30% against 24% on Wegovy, 19% to 23% against 11% to 17% on Zepbound, 12% to 17% against 6% to 7% on Mounjaro, and 8.5% to 8.8% against 3.1% to 5% on Ozempic.1,2,3,4 The tables count each reaction separately and do not say how many people had both.

That matters for treatment, because the remedy for one can tip into the other. In the trials of PEG, diarrhea was noted more often in the treatment arm, and diarrhea is among the most common side effects of the stimulant laxatives.6 Fiber is used in both directions: the nutrition advisory suggests fiber from foods for constipation and fiber in capsule or powder form when diarrhea is pronounced, because it adds bulk to the stool.8 An episode of diarrhea lasted a median of 3 days in the Wegovy trials, against 47 for constipation, so the two call for different amounts of patience.5

Short answers to common questions

Does Ozempic cause constipation?

Yes, in a small share of people. In the label trials it was reported by 5% on 0.5 mg and 3.1% on 1 mg, against 1.5% on placebo.

Does Zepbound cause constipation?

Yes. It was reported by 17% on 5 mg, 14% on 10 mg and 11% on 15 mg, against 5% on placebo.

How long does constipation last on a GLP-1?

The only measurement is for Wegovy 2.4 mg: a median of 47 days for one episode, against 35 days on placebo.

Does it go away?

In the Wegovy trials the share of people with constipation levelled off at about week 10, and it decreased over time in people who continued the drug after 20 weeks.

What helps constipation on a GLP-1?

NIDDK's home treatment is more fiber, more liquids, regular activity and a regular time for bowel movements. The nutrition advisory for GLP-1 therapy adds prunes or other dried fruit and a gradual increase in fiber.

Which laxative has the best evidence?

Polyethylene glycol. It is the over-the-counter agent with a strong recommendation for regular use in the 2023 guideline, and its effect lasted six months in trials. The trials were not in people on a GLP-1.

Do stool softeners work?

The guideline's panel searched for trials of docusate and issued no recommendation on it. It notes a paucity of data for docusate. The nutrition advisory for GLP-1 therapy says stool softeners may help in avoiding straining.

Can fiber make constipation worse?

Its common side effects are bloating and abdominal discomfort, and the guideline sees usually no benefit above 25 to 30 grams a day. NIDDK says to add it a little at a time and to drink more liquids with it.

Is a lower dose less constipating?

The label tables do not show that. Constipation was not more frequent on the higher doses of any of the four medicines.

Can constipation on a GLP-1 be dangerous?

It can be. Severe constipation including fecal impaction, ileus and intestinal obstruction have been reported after approval, and the labels say their frequency cannot be reliably estimated. Constipation with constant abdominal pain, vomiting, fever, blood or an inability to pass gas needs a doctor right away.

How this page was built

Every number was read in its source on November 20, 2026. The rates come from the current prescribing information of the four medicines. The timing and length of episodes come from a pooled analysis of the Wegovy trials, funded by the drug's maker. The laxative figures come from the full text of the 2023 AGA-ACG guideline, the home treatment from four NIDDK pages last reviewed in May 2018, and the food values from the USDA's SR Legacy database. For the two food trials we read the published abstracts and not the full papers.

The limits are these. None of the sources here tested a treatment for constipation specifically in people taking a GLP-1, so the guideline and the food trials are borrowed from constipation in general. The length of an episode is known for Wegovy only. The label rates count every report regardless of severity and say nothing about what one person should expect. This page does not suggest doses of any medicine or laxative; those are on the product label and with the prescriber.

Sources

  1. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 2, 5, 6 and 7. accessdata.fda.gov
  2. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 2, 5, 6 and 7. accessdata.fda.gov
  3. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 5, 6 and 7. accessdata.fda.gov
  4. MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; sections 5, 6 and 7. accessdata.fda.gov
  5. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab 2022;24:94-105. doi:10.1111/dom.14551
  6. Chang L, Chey WD, Imdad A, et al. American Gastroenterological Association-American College of Gastroenterology clinical practice guideline: pharmacological management of chronic idiopathic constipation. Gastroenterology 2023;164:1086-1106. doi:10.1053/j.gastro.2023.03.214
  7. National Institute of Diabetes and Digestive and Kidney Diseases. Constipation: Definition and Facts; Symptoms and Causes; Treatment; Eating, Diet, and Nutrition. Last reviewed May 2018, read November 20, 2026. niddk.nih.gov
  8. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring) 2025;33:1475-1503. doi:10.1002/oby.24336
  9. U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary Guidelines for Americans, 2020-2025. 9th edition, December 2020; chapter 4 and Appendix 1, Table A1-2. dietaryguidelines.gov
  10. U.S. Department of Agriculture, Agricultural Research Service. FoodData Central, SR Legacy (2018), read November 20, 2026; the entries for the 24 foods in the counter. fdc.nal.usda.gov
  11. Attaluri A, Donahoe R, Valestin J, et al. Randomised clinical trial: dried plums (prunes) vs. psyllium for constipation. Aliment Pharmacol Ther 2011;33:822-828. doi:10.1111/j.1365-2036.2011.04594.x
  12. Chey SW, Chey WD, Jackson K, Eswaran S. Exploratory comparative effectiveness trial of green kiwifruit, psyllium, or prunes in US patients with chronic constipation. Am J Gastroenterol 2021;116:1304-1312. doi:10.14309/ajg.0000000000001149

Related analyses

Log each dose and each symptom, and see how long an episode really lasts for you.

Open Dose Insider